Spyre Therapeutics Stock Market Value
| SYRE Stock | 27.00 0.50 1.82% |
| Symbol | Spyre |
Spyre Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Spyre Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spyre Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spyre Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Spyre Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Spyre Therapeutics or generate 0.0% return on investment in Spyre Therapeutics over 30 days. Spyre Therapeutics is related to or competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, Transcode Therapeutics, and Quoin Pharmaceuticals. Spyre Therapeutics is entity of United States More
Spyre Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spyre Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spyre Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.34 | |||
| Information Ratio | 0.0058 | |||
| Maximum Drawdown | 15.8 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 5.3 |
Spyre Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spyre Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spyre Therapeutics' standard deviation. In reality, there are many statistical measures that can use Spyre Therapeutics historical prices to predict the future Spyre Therapeutics' volatility.| Risk Adjusted Performance | 0.0313 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | 0.0051 | |||
| Treynor Ratio | 0.0421 |
Spyre Therapeutics Backtested Returns
At this point, Spyre Therapeutics is not too volatile. Spyre Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0187, which indicates the firm had a 0.0187% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Spyre Therapeutics, which you can use to evaluate the volatility of the company. Please validate Spyre Therapeutics' Coefficient Of Variation of 3235.74, semi deviation of 4.17, and Risk Adjusted Performance of 0.0313 to confirm if the risk estimate we provide is consistent with the expected return of 0.0695%. Spyre Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 2.56, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spyre Therapeutics will likely underperform. Spyre Therapeutics right now has a risk of 3.72%. Please validate Spyre Therapeutics expected short fall, as well as the relationship between the rate of daily change and relative strength index , to decide if Spyre Therapeutics will be following its existing price patterns.
Auto-correlation | -0.41 |
Modest reverse predictability
Spyre Therapeutics has modest reverse predictability. Overlapping area represents the amount of predictability between Spyre Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spyre Therapeutics price movement. The serial correlation of -0.41 indicates that just about 41.0% of current Spyre Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.41 | |
| Spearman Rank Test | -0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 22.61 |
Spyre Therapeutics lagged returns against current returns
Autocorrelation, which is Spyre Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Spyre Therapeutics' stock expected returns. We can calculate the autocorrelation of Spyre Therapeutics returns to help us make a trade decision. For example, suppose you find that Spyre Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Spyre Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Spyre Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Spyre Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Spyre Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Spyre Therapeutics Lagged Returns
When evaluating Spyre Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Spyre Therapeutics stock have on its future price. Spyre Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Spyre Therapeutics autocorrelation shows the relationship between Spyre Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Spyre Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out Spyre Therapeutics Correlation, Spyre Therapeutics Volatility and Spyre Therapeutics Alpha and Beta module to complement your research on Spyre Therapeutics. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Spyre Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.